GlassScriptPhysician profile
Donald J Halke
NPI 1962794016
$2,632.80
in general payments reported to CMS, 2019-2025
28 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $72.34 · 2021: $252 · 2022: $280 · 2023: $242 · 2024: $802 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,834.27 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.66 | 2019-2025 | Airsupra, Breztri |
| Abbvie INC. | $533.71 | 2021-2025 | |
| Amgen INC. | $194.71 | 2024-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $142.30 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Vanda Pharmaceuticals INC. | $120.59 | 2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $119.55 | 2023-2025 | Rexulti |
| Pfizer INC. | $92.54 | 2022-2025 | |
| Alkermes, INC. | $83.56 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.69 | 2022-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $73.57 | 2021-2023 | |
| Gilead Sciences, INC. | $73.24 | 2023-2025 | Epclusa |
| Ardelyx, INC. | $56.86 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $50.81 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $50.80 | 2019 | |
| Glaxosmithkline, LLC. | $48.61 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.12 | 2022-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $34.74 | 2025 | Auvelity |
| Amarin Pharma, INC. | $31.07 | 2019-2020 | |
| Lilly USA, LLC | $30.65 | 2023 | Jardiance, Emgality |
| Exact Sciences Corporation | $29.30 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $20.00 | 2024 | Minimed 780g |
| E.R. Squibb & Sons, L.L.C. | $19.87 | 2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.17 | 2021 | |
| Lundbeck LLC | $17.42 | 2024 | Rexulti |
| Astellas Pharma US INC | $13.59 | 2025 | Veozah |
| Allergan, INC. | $12.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Halke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.